-inc-logo.jpg?v=20240515130629 "Definium Therapeutics, Inc. logo"){kind=logo}
Wall Street Zen downgraded shares of Definium Therapeutics (NASDAQ:DFTX – Free Report) from a hold rating to a sell rating in a report released on Saturday morning.
Other analysts have also recently issued reports about the company. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Needham & Company LLC boosted their target price on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Finally, Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $49.23.
Read Our Latest Stock Report on Definium Therapeutics
Definium Therapeutics Stock Down 3.4%
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Analysts anticipate that Definium Therapeutics will post -2.27 EPS for the current fiscal year.
Insider Activity
In other news, CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This represents a 2.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 in the last quarter. 2.40% of the stock is owned by company insiders.
Institutional Investors Weigh In On Definium Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of DFTX. Sender Co & Partners Inc. purchased a new position in Definium Therapeutics during the 3rd quarter valued at $305,000. Scientech Research LLC bought a new position in Definium Therapeutics during the 3rd quarter worth about $286,000. Mercer Global Advisors Inc. ADV increased its holdings in Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after buying an additional 2,079 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Definium Therapeutics by 82.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock valued at $181,000 after acquiring an additional 6,903 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Definium Therapeutics by 259.0% in the third quarter. Russell Investments Group Ltd. now owns 13,703 shares of the company’s stock worth $162,000 after purchasing an additional 9,886 shares in the last quarter. 27.91% of the stock is owned by institutional investors.
Definium Therapeutics Company Profile
Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.
Featured Stories
- Five stocks we like better than Definium Therapeutics
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
